Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Thiopental and propofol are two separate intravenous anesthetic agents that may be used together in anesthesia practice. This is not a fixed-dose combination product but rather represents the concurrent or sequential use of both medications. **Thiopental** is a rapid-onset short-acting barbiturate that decreases cerebral metabolic oxygen requirements and cerebral blood flow. It has been traditionally used for induction of anesthesia and management of increased intracranial pressure. **Propofol** is a sedative-hypnotic agent that has largely replaced thiopental for induction of general anesthesia. It is known for its rapid recovery profile and fewer post-anesthetic side effects. When used together, these agents may complement each other's effects or be administered at different points during anesthesia management. The combination might be employed to achieve specific hemodynamic goals or to reduce the dose requirements of either agent alone.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on thiopental + propofol.